@article{Yuan2024, 
author = {Rong Yuan and Qiqi Xin and Weili Shi and Yu Miao and Zhengchuan Zhu and Yahui Yuan and Ying Chen and Xiaoning Chen and Sean Xiao Leng and Keji Chen and Weihong Cong},
title = {Tetramethylpyrazine and paeoniflorin combination (TMP-PF) alleviates atherosclerosis progress by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway},
year = {2024},
journal = {Food Science and Human Wellness},
volume = {13},
number = {5},
pages = {2642-2652},
keywords = {Angiogenesis, Atherosclerosis, Chinese medicine, Paeoniflorin, Plaque stability, Hyperlipemia, Tetramethylpyrazine},
url = {https://www.sciopen.com/article/10.26599/FSHW.2022.9250212},
doi = {10.26599/FSHW.2022.9250212},
abstract = {Atherosclerosis remains a great threat to human health worldwide. Previous studies found that tetramethylpyrazine (TMP) and paeonif lorin (PF) combination (TMP-PF) exerts anti-atherosclerotic effects in vitro. However, whether TMP-PF improves atherosclerosis in vivo needs further exploration. The present study aims to assess the anti-atherosclerotic properties of TMP-PF in ApoE-/- mice and explore the related molecule mechanisms. Results showed that TMP and high-dose TMP-PF decreased serum triglyceride and low-density lipoprotein cholesterol levels, suppressed vascular endothelial growth factor receptor 2 (VEGFR2) and nuclear receptor subfamily 4 group A member 1 (NR4A1) expression in aortic tissues, inhibited plaque angiogenesis, reduced plaque areas, and alleviated atherosclerosis in ApoE-/- mice. Also, TMP-PF exhibited a better modulation effect than TMP or PF alone. However, NR4A1 agonist abolished the anti-atherosclerotic effects of TMP-PF. In conclusion, TMP-PF was first found to alleviate atherosclerosis progression by reducing hyperlipemia and inhibiting plaque angiogenesis via the NR4A1/VEGFR2 pathway, indicating that TMP-PF had a positive effect on reducing hyperlipemia and attenuating atherosclerosis development.}
}